• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gracell Biotechnologies Inc. - American Depositary Shares (NQ:GRCL)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Gracell Biotechnologies Inc. - American Depositary Shares

< Previous 1 2 Next >
News headline image
Gracell Biotechnologies Acquisition Completed
February 22, 2024
From Gracell Biotechnologies Inc.
Via GlobeNewswire
News headline image
Gracell Biotechnologies Announces Shareholders’ Approval of Merger Agreement
February 20, 2024
From Gracell Biotechnologies Inc.
Via GlobeNewswire
Gracell Biotechnologies Inc. (NASDAQ: GRCL) is a Stock Spotlight on 2/7
February 07, 2024
Via Investor Brand Network
News headline image
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma
January 29, 2024
Further expands clinical development of FasTCAR-T GC012F in multiple myeloma amid ongoing U.S. trial evaluating therapy for treatment of relapsed/refractory multiple myeloma 
From Gracell Biotechnologies Inc.
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
January 16, 2024
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
AstraZeneca: Rebound in 2024 with double-digit earnings growth
January 11, 2024
AstraZeneca's stock rose 8.95% in the past month on a bullish outlook, driven by growing sales of cancer and diabetes drugs and a strategic acquisition 
Via MarketBeat
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
January 08, 2024
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RayzeBio, Inc. (Nasdaq – RYZB), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Daseke, Inc. (Nasdaq – DSKE), Karuna Therapeutics, Inc. (Nasdaq – KRTX)
January 04, 2024
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
GRACELL BIOTECHNOLOGIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Gracell Biotechnologies Inc. - GRCL
December 31, 2023
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RayzeBio, Inc. (Nasdaq – RYZB), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Daseke, Inc. (Nasdaq – DSKE), Karuna Therapeutics, Inc. (Nasdaq – KRTX)
December 26, 2023
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
GRCL Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Gracell Biotechnologies Inc. Is Fair to Shareholders
December 26, 2023
From Halper Sadeh LLC
Via Business Wire
News headline image
AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases
December 26, 2023
From AstraZeneca
Via Business Wire
News headline image
Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases
December 26, 2023
From Gracell Biotechnologies Inc.
Via GlobeNewswire
News headline image
Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus
December 21, 2023
From Gracell Biotechnologies Inc.
Via GlobeNewswire
News headline image
Gracell Biotechnologies Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma at ASH 2023
December 11, 2023
From Gracell Biotechnologies Inc.
Via GlobeNewswire
News headline image
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus
November 27, 2023
From Gracell Biotechnologies Inc.
Via GlobeNewswire
News headline image
Gracell Biotechnologies to Participate in Inaugural Cell Therapy for Autoimmune Disease Summit
November 16, 2023
From Gracell Biotechnologies Inc.
Via GlobeNewswire
News headline image
Gracell Biotechnologies Reports Third Quarter 2023 Unaudited Financial Results and Provides Corporate Update
November 13, 2023
From Gracell Biotechnologies Inc.
Via GlobeNewswire
News headline image
Gracell Biotechnologies Wins Overall Immunology Solution of the Year by BioTech Breakthrough Awards Program
November 08, 2023
From Gracell Biotechnologies Inc.
Via GlobeNewswire
News headline image
Gracell Biotechnologies to Present Updated Results from BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 65ᵗʰ American Society of Hematology Annual Meeting & Exposition
November 02, 2023
From Gracell Biotechnologies Inc.
Via GlobeNewswire
News headline image
Gracell Biotechnologies to Participate in Four Upcoming Investor Conferences
November 01, 2023
From Gracell Biotechnologies Inc.
Via GlobeNewswire
News headline image
Gracell Biotechnologies to Present Data Highlighting Preclinical Efficacy of SMART CART™ Against Solid Tumors at Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
October 31, 2023
From Gracell Biotechnologies Inc.
Via GlobeNewswire
News headline image
Gracell Biotechnologies to Report Third Quarter 2023 Financials on Monday, November 13, 2023
October 30, 2023
From Gracell Biotechnologies Inc.
Via GlobeNewswire
News headline image
Gracell Biotechnologies Reports Updated Clinical Data for FasTCAR-T GC012F for High-Risk, Newly Diagnosed Multiple Myeloma, Demonstrating 100% Stringent Complete Response Rate
September 27, 2023
From Gracell Biotechnologies Inc.
Via GlobeNewswire
News headline image
Gracell Biotechnologies Doses First Patient in Phase 1b/2 Clinical Trial in U.S. Evaluating GC012F for Treatment of Relapsed/Refractory Multiple Myeloma
September 26, 2023
From Gracell Biotechnologies Inc.
Via GlobeNewswire
News headline image
Gracell Biotechnologies’ CEO Dr. William Cao Named to Prestigious PharmaVoice 100, Honoring Most Inspiring Life Science Leaders
September 19, 2023
From Gracell Biotechnologies Inc.
Via GlobeNewswire
News headline image
Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences
September 14, 2023
From Gracell Biotechnologies Inc.
Via GlobeNewswire
News headline image
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
August 24, 2023
From Gracell Biotechnologies Inc.
Via GlobeNewswire
News headline image
Gracell Biotechnologies Reports Second Quarter 2023 Unaudited Financial Results and Provides Corporate Update
August 14, 2023
From Gracell Biotechnologies Inc.
Via GlobeNewswire
News headline image
Gracell Biotechnologies to Report Second Quarter 2023 Financials on Monday, August 14, 2023
July 31, 2023
From Gracell Biotechnologies Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap